Cuixiang Meng
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Using the nose as a factory to secrete proteins into the lungs or circulation.
Journal: Molecular therapy. Advances
Published: November 17, 2025
Assessment of F/HN-pseudotyped lentiviral vector following intravenous delivery to mice.
Journal: Gene therapy
Published: November 14, 2025
F/HN-pseudotyped lentiviral vector efficiently transduces non-human primate airways with no evidence of relevant toxicity.
Journal: Molecular therapy. Advances
Published: May 20, 2025
Correction of a chronic pulmonary disease through lentiviral vector-mediated protein expression.
Journal: Molecular therapy. Methods & clinical development
Published: January 12, 2022
The murine lung as a factory to produce secreted intrapulmonary and circulatory proteins.
Journal: Gene therapy
Published: February 06, 2018
Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.
Journal: Thorax
Published: January 27, 2016
Ex Vivo and In Vivo Lentivirus-Mediated Transduction of Airway Epithelial Progenitor Cells.
Journal: Current gene therapy
Published: June 26, 2015
Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial.
Journal: The Lancet. Respiratory medicine
Published: May 05, 2015
Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy.
Journal: American journal of respiratory and critical care medicine
Published: September 08, 2012
Assessment of the nuclear pore dilating agent trans-cyclohexane-1,2-diol in differentiated airway epithelium.
Journal: The journal of gene medicine
Published: June 20, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026